NextBio

Help
Description: Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Rosiglitazone, a member of the drug group known as the thiazolidinediones or 'insulin sensitizers', is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Rosiglitazone targets insulin resistance and, hence, is used alone or with metformine or sulfonylurea to improve glycemic control in patients with type 2 diabetes mellitus.
Mechanism of Action: Rosiglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.
Indication: For the treatment of Type II diabetes mellitus
Half Life: 3-4 hours
View Complete Description



Data Correlations | 19 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
PPARG 100 100
FABP4 100 100
RBP7 98 98
RGD1564107_predicted 87 87
ADFP 87 87
ANGPTL4 86 86
View Top Genes
Biogroups category icon Biogroups
Score Help
PPAR Signaling Pathway 100 100
Calycin 95 95
Lipocalin-related protein and Bos/C… 95 95
Calycin-like 95 95
Focal Adhesion 94 94
Fatty Acid Metabolism 93 93
View Top Biogroups

Individual Studies

  • Retinoid response in PPARg and RARa ligand treated dendritic cells

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    Our data indicated that activation of the PPARg nuclear receptor induces a retinoid response in human dendritic cells. In order to assess the contribution of retinoid signaling to the PPARg response we decided to use a combination of pharmacological activators and inhibitors of these pathways. Cells…

    Authors: Nagy Laszlo, Szatmari Istvan

    Organization: University of Debrecen Department of Bio…

  • Synergy between PPARgamma ligands and platinum-based drugs in cancer

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    PPAR-gamma is a member of the nuclear receptor family for which agonist ligands have anti-growth effects. However, clinical studies using PPAR-gamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPAR-gamma activation with chemotherapeutic agents in …

    Authors: Girnun GD, Naseri E, Vafai SB et al.

    Organization: Dana-Farber Cancer Institute Cancer Biol…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Rosiglitazone.

View All Author iconAuthors
  • Dahong Yu
  • Bernard Zinman
  • Barbara G Kravitz
  • Rury R Holman
  • Katherine Esposito
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • GlaxoSmithKline
  • Eunice Kennedy Shriver National Institute of Child Health and Human De…
  • Massachusetts General Hospital
  • Leiden University Medical Center
  • Baskent University
View All Affiliations icon Organizations
  • VA Puget Sound Health Care System and University of Washington
  • McMaster University
  • Newcastle Diabetes Centre and Newcastle University
  • University of Pennsylvania School of Medicine
  • Université Pierre et Marie Curie

Clinical Trials | 336 trials

Help for Clinical Trials View All

© 2009 NextBio